Published in J Clin Oncol on December 13, 2010
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol (2013) 3.87
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol (2014) 2.45
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract (2012) 1.36
Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26
Treatment of HER2-positive breast cancer. Breast (2013) 1.09
Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer (2013) 1.05
Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer (2013) 1.01
TP53 status and response to treatment in breast cancers. J Biomed Biotechnol (2011) 0.99
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review. Breast Cancer Res (2015) 0.95
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. Oncologist (2014) 0.95
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol (2015) 0.94
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. J Clin Oncol (2016) 0.93
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol (2017) 0.90
Targeted therapy in her2-positive metastatic breast cancer: a review of the literature. Curr Oncol (2015) 0.89
Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist (2012) 0.88
Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics (2011) 0.83
Newer therapies for the treatment of metastatic breast cancer: a clinical update. Indian J Pharm Sci (2013) 0.81
Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis. PLoS One (2015) 0.80
Trastuzumab in advanced breast cancer--a decade of experience in Germany. BMC Cancer (2014) 0.80
Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res (2016) 0.79
National consensus in China on diagnosis and treatment of patients with advanced breast cancer. Ann Transl Med (2015) 0.79
Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series. J Oncol (2012) 0.79
Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series. ISRN Oncol (2014) 0.79
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2012) 0.79
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer. Oncologist (2013) 0.78
Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight. J Clin Oncol (2010) 0.78
Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations. Clin Med Insights Oncol (2012) 0.78
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. J Clin Pharmacol (2016) 0.77
Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast Center. Geburtshilfe Frauenheilkd (2014) 0.77
Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. Breast Care (Basel) (2014) 0.76
First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study. Pan Afr Med J (2016) 0.76
The expanding role of pertuzumab in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2015) 0.76
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer. Oncologist (2012) 0.75
The trastuzumab and vinorelbine combination: an alternative to taxane-based chemotherapy for early-stage and locally advanced her2-positive breast cancer. Curr Oncol (2014) 0.75
Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer. Chin J Cancer Res (2016) 0.75
Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. Springerplus (2015) 0.75
Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer. Breast Care (Basel) (2016) 0.75
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study. Breast Cancer (Dove Med Press) (2016) 0.75
Defining the optimal sequence for the systemic treatment of metastatic breast cancer. Clin Transl Oncol (2016) 0.75
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness. Ther Adv Med Oncol (2016) 0.75
Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials. Oncologist (2015) 0.75
Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results. Oncologist (2017) 0.75
Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer. ESMO Open (2017) 0.75
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol (2010) 3.92
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A (2008) 2.64
Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol (2010) 2.53
Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol (2008) 2.17
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Position paper: breast cancer screening, diagnosis, and treatment in Denmark. Acta Oncol (2014) 2.04
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res (2006) 2.02
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol (2012) 2.00
Low concordance of biomarkers in histopathological and cytological material from breast cancer. Histopathology (2014) 1.96
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
[Should complementary therapies be offered in hospitals?]. Tidsskr Nor Laegeforen (2004) 1.91
Correlation test to assess low-level processing of high-density oligonucleotide microarray data. BMC Bioinformatics (2005) 1.86
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Associations between home death and GP involvement in palliative cancer care. Br J Gen Pract (2009) 1.84
Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol (2009) 1.81
Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol (2003) 1.71
Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol (2007) 1.68
Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. Genome Res (2011) 1.67
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.66
Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer (2013) 1.61
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol (2006) 1.52
Symptoms 10-17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial. Radiother Oncol (2010) 1.50
Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol (2008) 1.47
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast (2009) 1.42
Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. Clin Cancer Res (2010) 1.41
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res (2006) 1.38
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res Treat (2010) 1.31
Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res (2011) 1.30
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res (2002) 1.25
Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol (2005) 1.22
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat (2010) 1.20
Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage (2007) 1.17
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
Improvements in patient satisfaction at an outpatient clinic for patients with breast cancer. Acta Oncol (2006) 1.16
Implementation of a clinical dementia guideline. A controlled study on the effect of a multifaceted strategy. Scand J Prim Health Care (2003) 1.13
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat (2010) 1.13
Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies. Clin Chem (2004) 1.13
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Clinical characterization and the mutation spectrum in Swedish adenomatous polyposis families. BMC Med (2008) 1.12
Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res (2007) 1.11
Dopamine D(1) receptors and age differences in brain activation during working memory. Neurobiol Aging (2009) 1.09
Socio-economic factors and breast cancer survival--a population-based cohort study (Sweden). Cancer Causes Control (2005) 1.09
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst (2005) 1.09
The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol (2008) 1.09
Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med (2006) 1.08
Congruence between preferred and actual place of care and death among Danish cancer patients. Palliat Med (2012) 1.07
Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis (2003) 1.07
Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol (2005) 1.06
Validity and representativity in the Danish Breast Cancer Cooperative Group--a study on protocol allocation and data validity from one county to a multi-centre database. Acta Oncol (2003) 1.06
Fruits and vegetables intake differentially affects estrogen receptor negative and positive breast cancer incidence rates. J Nutr (2003) 1.05
[18F]flumazenil binding to central benzodiazepine receptor studies by PET--quantitative analysis and comparisons with [11C]flumazenil. Neuroimage (2008) 1.05
Thyroid function in women after multimodal treatment for breast cancer stage II/III: comparison with controls from a population sample. Int J Radiat Oncol Biol Phys (2009) 1.04
Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women. Eur J Oncol Nurs (2008) 1.04
Prevalence and risk of depressive symptoms 3-4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer. Breast Cancer Res Treat (2008) 1.04
Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav Immun (2011) 1.03
Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res (2012) 1.02
Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res (2010) 1.01
Cancer surviving patients' rehabilitation - understanding failure through application of theoretical perspectives from Habermas. BMC Health Serv Res (2008) 1.01
Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med (2014) 0.99
How to treat male breast cancer. Breast (2007) 0.99
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol (2008) 0.99
Health-related quality of life in long-term breast cancer survivors: nationwide survey in Denmark. Breast Cancer Res Treat (2006) 0.99
Individual psychosocial support for breast cancer patients: a randomized study of nurse versus psychologist interventions and standard care. Cancer Nurs (2007) 0.98
Predictors and course of chronic fatigue in long-term breast cancer survivors. J Cancer Surviv (2010) 0.98
Long-term inequalities in breast cancer survival--a ten year follow-up study of patients managed within a National Health Care System (Sweden). Acta Oncol (2008) 0.98
Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. Ann Surg (2011) 0.97
Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol (2007) 0.97
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med (2010) 0.97
[(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging (2003) 0.96
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res Treat (2011) 0.96
Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat (2010) 0.96
Fear of recurrence in long-term testicular cancer survivors. Psychooncology (2009) 0.96
Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol (2005) 0.95
Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer (2006) 0.95